Checkpoint Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details)					1 Months Ended					3 Months Ended		12 Months Ended
Stockholders' Equity - Additional Information (Details)	Jan. 01, 2025 shares	May 13, 2024 $ / shares shares	Jan. 01, 2024	Mar. 17, 2015	Mar. 31, 2025 USD ($) multiplier Vote $ / shares shares	Jan. 31, 2025 USD ($) $ / shares shares	Nov. 30, 2024 USD ($) $ / shares shares	Jul. 31, 2024 USD ($) $ / shares shares	Jan. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2025 USD ($) multiplier Vote $ / shares shares	Mar. 31, 2024 USD ($) shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)	Mar. 09, 2025 $ / shares	May 16, 2024 shares	Mar. 31, 2023 USD ($)
Stockholders' Equity
Common stock, increase in the number of authorized shares (in shares)		95,000,000
Common stock, shares authorized		175,000,000			175,000,000					175,000,000		175,000,000
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001			$ 0.0001					$ 0.0001		$ 0.0001
Common stock, shares outstanding					83,063,733					83,063,733		53,640,422
Common stock, shares issued					83,063,733					83,063,733		53,640,422
Class of warrants exercise price \| $ / shares					$ 1.66	$ 2.84	$ 2.821			$ 1.66				$ 3.62
Shares held in abeyance							1,437,000
Total gross proceeds from Issuance of common stock \| $											$ 14,000,000
Amount of commissions and other transaction costs \| $											$ 1,213,000
Proceeds from Warrant \| $					$ 36,000,000	$ 2,100,000	$ 9,200,000			$ 38,124,000
Number of common stock warrants exercised					21,691,003	740,000	3,256,269
Pre-funded warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares								$ 0.0001	$ 0.0001
Non-vested restricted stock
Stockholders' Equity
Total unrecognized compensation cost related to non-vested \| $					$ 11,800,000					$ 11,800,000
Weighted average period (in years)										1 year 9 months 18 days
Restricted Stock Units
Stockholders' Equity
Number of units outstanding					0					0
2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized		18,000,000
Shares are available for issuance					4,860,406					4,860,406
Plans expires (in years)		10 years
April 2023 Direct Offering
Stockholders' Equity
Shelf registration statement remaining authorized securities \| $																$ 150,000,000
January 2024 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold									1,275,000
Purchase price per share \| $ / shares									$ 1.805
Class of warrants exercise price \| $ / shares									$ 1.8049
Total gross proceeds from Issuance of common stock \| $									$ 14,000,000
Net proceeds from offering \| $									12,600,000
Amount of commissions and other transaction costs \| $									$ 1,400,000
January 2024 Registered Direct Offering \| Pre-funded warrants
Stockholders' Equity
Number of warrants issued									6,481,233
Class of warrants exercise price \| $ / shares									$ 1.8049
January 2024 Registered Direct Offering \| Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares									$ 2.2563
Number of warrants issued and sold to purchase shares									465,374
July 2024 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold								1,230,000
Purchase price per share \| $ / shares								$ 2.05
Number of warrants issued								4,623,659
Class of warrants exercise price \| $ / shares								$ 2.0499
Total gross proceeds from Issuance of common stock \| $								$ 12,000,000
Net proceeds from offering \| $								11,000,000
Amount of commissions and other transaction costs \| $								$ 1,000,000
July 2024 Registered Direct Offering \| Pre-funded warrants
Stockholders' Equity
Number of warrants issued								4,623,659
Class of warrants exercise price \| $ / shares								$ 2.0499
July 2024 Registered Direct Offering \| Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares								$ 2.5625
Number of warrants issued and sold to purchase shares								351,220
Fortress Biotech, Inc
Stockholders' Equity
Number of shares issued and sold	2,386,808									18,500	193,905
Percentage of annual equity fee			2.50%							2.50%	2.50%
Issuance of common shares - Founders agreement \| $										$ 52,000	$ 396,000
Percentage of shares issued for offering and annual equity fee	2.50%
Common stock shares issuable															1,492,915
Fortress Biotech, Inc
Stockholders' Equity
Shelf registration statement remaining authorized securities \| $					$ 65,700,000					$ 65,700,000
Related Party \| Fortress Biotech, Inc
Stockholders' Equity
Number of shares issued and sold	2,386,808
Percentage of shares issued for offering and annual equity fee	2.50%			2.50%
Non-cash research and development expenses \| $												$ 7,600,000	$ 3,400,000
Common Stock
Stockholders' Equity
Number of votes per share \| Vote					1					1
Multiplier to calculate voting rights per class A common share \| multiplier					1.1					1.1
Number of non assessable shares issued upon conversion					1					1
Number of common stock warrants exercised										23,868,003
Common Stock \| January 2024 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold									1,275,000
Class of warrants exercise price \| $ / shares									$ 1.68
Expiration term of warrants (in years)									5 years
Common Stock \| January 2024 Registered Direct Offering \| Maximum
Stockholders' Equity
Number of warrants issued and sold to purchase shares									7,756,233
Common Stock \| July 2024 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold								1,230,000
Class of warrants exercise price \| $ / shares								$ 2.05
Expiration term of warrants (in years)								5 years
Common Stock \| July 2024 Registered Direct Offering \| Maximum
Stockholders' Equity
Number of warrants issued and sold to purchase shares								5,853,659
Warrants
Stockholders' Equity
Expiration term of warrants (in years)					3 years 8 months 1 day					3 years 8 months 1 day		3 years 1 month 2 days
Common Class A
Stockholders' Equity
Common stock, shares authorized		700,000
Common stock, shares outstanding					700,000					700,000		700,000
Common stock, shares issued					700,000					700,000		700,000